Loading stock data…
Gilead Sciences (GILD)
$129.31-1.55 (-1.18%)
Market ClosedLast close Jul 24
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gilead Sciences, Inc. in the Healthcare sector is trading at $129.31 with a market capitalization of $157.6B. Wall Street consensus targets $157.56 (27 analysts), implying a +21.8% move over the next 12 months. The stock is currently 18% below its 52-week high of $157.29, remaining 0.6% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.96B↓ | $7.92B↑ | $7.77B↑ | $7.08B↑ | $6.67B |
| Gross Profit | $5.51B↓ | $6.30B↑ | $6.20B↑ | $5.58B↑ | $5.13B |
| Operating Income | $2.69B↓ | $2.99B↓ | $3.50B↑ | $2.72B↑ | $2.49B |
| Net Income | $2.02B↓ | $2.18B↓ | $3.05B↑ | $1.96B↑ | $1.31B |
Peer Comparison
JNJUNHPFE
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$157.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.47%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.19%
Volume
Today's trading volume
5.30M
Recent News
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...
3 Market-Beating Stocks with Solid Fundamentals
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.